The destruction of pancreatic beta-cells in type 1 diabetes mellitus is mediated by autoreactive T-lymphocyte clones. We initiated a prospective randomized controlled trial of polyclonal rabbit anti-T-cell globulin (ATG) in patients with type 1 diabetes within 4 weeks of diagnosis and with residual post-glucagon C-peptide levels still over 0.3 nmol/l. ATG was administered as an initial bolus of 9 mg/kg followed by 3 consecutive doses of 3 mg/kg. An interim analysis was performed to establish whether any significant changes in C-peptide production and insulin requirement had occurred that would justify the continuation of this pilot study. By May 2004, 11 subjects were assigned to treatment with ATG along with intensified insulin therapy and 6 to intensified insulin therapy with placebo, and were followed for a period of at least 6 months. During the first 12 months a significant difference in the insulin dose trends was found between the groups (p = 0.010) with a lower insulin dosage in the ATG group. There was also a difference in the glucagon stimulated C-peptide level trends of marginal significance (p = 0.068). Compared to values at screening, stimulated C-peptide levels significantly improved in the ATG group (p = 0.012) but not in the placebo group. Complete diabetes remission occurred in 2 patients in the ATG and in none of the placebo group. Glycosylated hemoglobin at 12 months tended to be lower in the ATG group (p = 0.088). Significant adverse effects of ATG treatment, mainly transient fever and moderate symptoms of serum sickness (7 and 6 subjects, respectively) were observed during the first month only. The interim analysis of this ongoing study suggests that short-term ATG therapy in type 1 diabetes of recent onset contributes to the preservation of residual C-peptide production and to lower insulin requirements in the first year following diagnosis.

Diabetes Center Institute for Clinical and Experimental Medicine Videnska 1958 9 14021 Prague 4 Czech Republic

Zobrazit více v PubMed

Devendra D, Liu E, Eisenbarth GS. Type 1 diabetes: recent developments. BMJ. 2004;328:750–754. PubMed PMC

Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001;358:221–229. PubMed

Roep BO. The role of T cells in the pathogenesis of type 1 diabetes: From cause to cure. Diabetologia. 2003;46(3):305–321. PubMed

Winter WE, Schatz D. Prevention strategies for type 1 diabetes mellitus. Biodrugs. 2003;17:39–64. PubMed

Nerup J. In: Andreani D, Kolb H, Pozzili P. Immunotherapy of type 1 diabetes. John Willey and Sons; 1989. Rationale of immune intervention of type 1 diabetes. ; pp. 5–11.

Chatenoud L. Restoration of self-tolerance is a feasible approach to controlling ongoing beta-cell specific autoreactivity: its prevalence for treatment in established diabetes and islet transplantation. Diabetologia. 2001;44:521–536. PubMed

Skyler JS, Lorenz TJ, Schwatz S, Eisenbarth GS, Einhorn D, Palmer JP, Marks JB, Greenbaum C, Saria EA, Byers V. Effects of an anti-CD5 immunoconjugate (CD5-Plus) in recent onset type 1 diabetes mellitus: a preliminary investigation. J Diab Comp. 1993;7:224–232. PubMed

Vialetts B, Vague P. Treatment of diabetes by monoclonal antibodies. Lessons from a pilot study using anti-IL-2 receptor MoAb in recently diagnosed diabetic patients. Diabetes Prev Ther. 1991;5:21–22.

Boitard C, Timsit J, Assan R, Mogenet A, Debussche X, Kaloustlan E, Attali JR, Chanson P, Chatenoud L, Woodworth T et al. Treatment of type 1 diabetes mellitus with DAB486-IL2, a toxin conjugate witch targets activated T-lymphocytes. Diabetologia. 1992;35(suppl 1):A218.

Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman S, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med. 2002;346:1692–1698. PubMed

Michallet MC, Preville X, Flacher M, Fournel S, Genestier L, Revillard JP. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation. 2003;75:657–662. PubMed

Pistillo MP, Tazzari PL, Bonifazi F, Bandini G, Kato T, Matsui T, Nishioka K, Conte R, Ferrara GB. Detection of a novel specificity (CTLA-4) in ATG/TMG globulins and sera from ATG-treated leukemic patients. Transplantation. 2002;73:1295–1302. PubMed

Schatz DA, Riley WJ, Silverstein JH, Barett DJ. Long-term immunoregulatory effects of therapy with corticosteroids and anti-thymocyte globulin. Immunoparm Immunotoxicol. 1989;11:269–287. PubMed

Eisenbarth GS, Srikanta S, Jackson R, Rabinowe S, Dolinar R, Aoki T, Morris MA. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diab Res. 1985;2:271–276. PubMed

Maes BD, Vanrenterghem YF. Induction with polyclonal antibodies. Curr Opin Organ Transplant. 1999;4:305–311.

Saudek F, Adamec M, Koznarova R, Boucek P, Voska L. Low rejection rate with high-dose ATG bolus therapy in simultaneous pancreas and kidney transplantation. Transplant Proc. 2001;33:2304–2306. PubMed

Stratton RJ, Wolson H, Black CM. Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology. 2001;40:84–88. PubMed

Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis. A randomized pilot study. Neurology. 2003;61:260–262. PubMed

Jeppsson JO, Kobold U, Barr J, Finke A, Hoelzel W, Hoshino T, Miedema K, Mosca A, Mauri P, Paroni R et al. Approved IFCC reference method for the measurement of HbA1c in human blood. Clin Chem Lab Med. 2002;40:78–89. PubMed

Olerup O, Aldener A, Fogdell A. HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. Tissue Antigens. 1993;41:119–134. PubMed

Chatenoud L, Ferran C, Legendre C, Thouard I, Merite S, Reuter A, Gevaert Y, Kreis H, Franchimont P, Bach JF. In vivo cell activation following OKT3 administration: systemic cytokine release and modulation by corticosteroids. Transplantaton. 1990;49:697–702. PubMed

Herold KC, Burton JB, Francois F, Poumian-Ruiz E, Glandt M, Bluestone J. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala) J Clin Invest. 2003;111:409–418. PubMed PMC

Leimenstoll G, Zerrenthin N, Niedermayer W, Steinmann J. An antilymphocyte globulin of rabbit origin inhibits the antigen induced activation of alloreactive T cells by blocking CD2. Transplant Proc. 1991;23:982–984. PubMed

Bonnefoy-Berard N, Revillard JP. Mechanism of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant. 1996;15:435–442. PubMed

Starzl ET, Murase N, Abu-Elmagd K, Gray EA, Shapiro R, Eghtesad B, Corry RJ, Jordan ML, Fontes P, Gayowski T et al. Tolerogenic immunosuppression for organ transplantation. Lancet. 2003;361:1502–1510. PubMed PMC

Shapiro R, Jordan ML, Basu A, Scantlebury V, Potdar S, Tan HP, Gray EA, Randhawa PS, Murase N, Zeevi A et al. Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg. 2003;238:520–525. PubMed PMC

Diabetes Control and Complications Trial Research Study Group. Effects of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial: a randomized, controlled trial. Ann Intern Med. 1998;128:517–523. PubMed

Greenbaum CJ, Harrison LC. Guidelines for intervention trials in subjects with newly diagnosed type 1 diabetes. Diabetes. 2003;52:1059–1065. PubMed

Imaging the Beta-cell mass: why and how